Peptide Schedule
Orexin (Hypocretin)33 residuesQPLPDCCRQKTCSCRLYELLHGAGNHAAGILTMEach bubble = one amino acid. Size = residue mass. Color = chemical class.Orexin (Hypocretin) Dosage Calculator
Orexin-A and Orexin-B, also known as Hypocretin-1 and Hypocretin-2, are excitatory neuropeptides synthesized by a discrete population of neurons in the lateral and perifornical hypothalamus.
10mcg · Daily
Summary: Add 2mL BAC water to your 0.5mg vial. Draw to 4.0 units on a U-100 syringe for a 10mcg dose. This vial will last 50 doses.
Cycle Planner
Orexin (Hypocretin) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~30 minutes (Orexin-A); ~5 minutes (Orexin-B)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Orexin (Hypocretin) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 10mcg | Daily |
| Moderate | 30mcg | Daily |
| Aggressive | 50mcg | 2x Daily |
Note: Orexin-A (Hypocretin-1) and Orexin-B (Hypocretin-2) are hypothalamic neuropeptides that regulate wakefulness, appetite, and reward-driven behavior. Discovered independently by two groups in 1998, they are produced by a small cluster of approximately 70,000 neurons in the lateral hypothalamus that project widely throughout the brain and spinal cord. Orexin-A is a 33-amino-acid peptide with two disulfide bonds, making it more stable than the 28-amino-acid Orexin-B. Loss of orexin-producing neurons is the hallmark pathology of narcolepsy type 1 (with cataplexy). These peptides act on two G-protein-coupled receptors, OX1R and OX2R. Current research use focuses on intranasal and intracerebroventricular delivery in animal models. The native peptides remain strictly research-only and are not approved for human therapeutic use.
About Orexin (Hypocretin)
Orexin-A and Orexin-B, also known as Hypocretin-1 and Hypocretin-2, are excitatory neuropeptides synthesized by a discrete population of neurons in the lateral and perifornical hypothalamus. Their discovery in 1998 by both the Sakurai and de Lecea laboratories represented a watershed moment in sleep neuroscience, linking a single neuropeptide system to the regulation of wakefulness, feeding behavior, autonomic tone, and reward processing. Orexin-A is a 33-amino-acid peptide stabilized by two intramolecular disulfide bonds and an N-terminal pyroglutamyl modification, conferring relatively high stability and the ability to cross the blood-brain barrier in small quantities. Orexin-B is a 28-amino-acid linear peptide that is less stable and does not cross the blood-brain barrier as readily. Both peptides are derived from a common 131-amino-acid precursor, prepro-orexin, through proteolytic cleavage. These neuropeptides bind to two G-protein-coupled receptors: OX1R, which has a ten-fold selectivity for Orexin-A over Orexin-B, and OX2R, which binds both peptides with similar affinity. OX2R is considered the primary mediator of wake-promoting effects, while OX1R plays a larger role in reward and autonomic regulation. Dual orexin receptor antagonists (DORAs) such as suvorexant and lemborexant are FDA-approved for the treatment of insomnia, validating the orexin system as a major therapeutic target. The loss of orexin-producing neurons, likely through an autoimmune mechanism, causes narcolepsy type 1, a condition characterized by excessive daytime sleepiness and cataplexy. Cerebrospinal fluid orexin-A levels below 110 pg/mL are a diagnostic biomarker for this disorder. Research into orexin-A agonists and replacement therapies aims to restore wakefulness in narcoleptic patients. Animal studies have demonstrated that intranasal delivery of Orexin-A can enhance alertness and cognitive performance in sleep-deprived primates, though no orexin agonist peptide has yet reached clinical trials in humans.